• 1
    Brockhoff G. DNA and proliferation analysis in flow cytometry. In: SackU,TámokA,RotheG, editors. Cellular Diagnostics—Basic Principles, Methods and Clinical Applications of Flow Cytometry. Freiburg, Germany: Karber Publishing; 2008. pp 390425. ISBN: 978-3-8055-8555-2.
  • 2
    Brockhoff G,Heckel B,Schmidt-Bruecken E,Plander M,Hofstaedter F,Vollmann A,Diermeier S. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40: 488507.
  • 3
    Diermeier S,Horvath G,Knuechel-Clarke R,Hofstaedter F,Szollosi J,Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304: 604619.
  • 4
    Diermeier S,Schmidt-Bruecken E,Kubbies M,Kunz-Schughart LA,Brockhoff G. Exposure to continuous bromodeoxyuridine (BrdU) differentially affects cell cycle progression of human breast and bladder cancer cell lines. Cell Prolif 2004; 37: 195206.
  • 5
    Ormerod MG,Kubbies M. Cell cycle analysis of asynchronous cell populations by flow cytometry using bromodeoxyuridine label and Hoechst-propidium iodide stain. Cytometry 1992; 13: 678685.
  • 6
    Wilson GD. Analysis of DNA-measurement of cell kinetics by the bromodeoxyuridine/anti-bromodeoxyuridine method. In: OrmerodMG, editor. Flow Cytometry: A Practical Approach,2 ed. Oxford, UK: Oxford University Press; 1994. Vol. 8, pp 137156. ISBN: 978-0-19-963824-6.
  • 7
    Dolbeare F,Selden JR. Immunochemical quantitation of bromodeoxyuridine: Application to cell-cycle kinetics. Methods Cell Biol 1994; 41: 297316.
  • 8
    Takagi S,McFadden ML,Humphreys RE,Woda BA,Sairenji T. Detection of 5-bromo-2-deoxyuridine (BrdUrd) incorporation with monoclonal anti-BrdUrd antibody after deoxyribonuclease treatment. Cytometry 1993; 14: 640648.
  • 9
    Salic A,Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008; 105: 24152420.
  • 10
    Buck SB,Bradford J,Gee KR,Agnew BJ,Clarke ST,Salic A. Detection of S-phase cell cycle progression using 5-ethynyl-2′-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2′-deoxyuridine antibodies. Biotechniques 2008; 44: 927929.
  • 11
    Kubbies M,Hoehn H,Schindler D,Chen YC,Rabinovitch PS. Cell cycle analysis via BrdU-Hoechst flow cytometry: Principles and applications. In: YenA, editor. Flow Cytometry: Advanced Research and Clinical Applications, Vol. 11. Boca Raton, Florida: CRC Press; 1989. pp 528.
  • 12
    Poot M,Hoehn H,Kubbies M,Grossmann A,Chen Y,Rabinovitch PS. Cell-cycle analysis using continuous bromodeoxyuridine labeling and Hoechst 33358-ethidium bromide bivariate flow cytometry. Methods Cell Biol 1994; 41: 327340.
  • 13
    Goz B. The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev 1977; 29: 249272.
  • 14
    Balzarini J,De Clercq E,Kiefer G,Keppeler K,Buchele A. Antitumor cell and antimetabolic effects of 5-ethyl-2′-deoxyuridine and 5′-substituted 5-ethyl-2′-deoxyuridine derivatives. Invest New Drugs 1984; 2: 3547.
  • 15
    Meuth M,Green H. Induction of a deoxycytidineless state in cultured mammalian cells by bromodeoxyuridine. Cell 1974; 2: 109112.
  • 16
    Rabinovitch PS. Regulation of human fibroblast growth rate by both noncycling cell fraction transition probability is shown by growth in 5-bromodeoxyuridine followed by Hoechst 33258 flow cytometry. Proc Natl Acad Sci USA 1983; 80: 29512955.
  • 17
    Feng L,Achanta G,Pelicano H,Zhang W,Plunkett W,Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med 2000; 5: 597604.
  • 18
    Damaraju D,Damaraju VL,Brun M,Mowles D,Kuzma M,Berendt RC,Sawyer MB,Cass CE. Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: Characterization of a novel nucleobase transport activity. Biochem Pharmacol 2008; 75: 19011911.
  • 19
    Ho GH,Calvano JE,Bisogna M,Abouezzi Z,Borgen PI,Cordon-Cardo C,van Zee KJ. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. Breast Cancer Res Treat 2001; 65: 225232.
  • 20
    Fedier A,Fink D. Mutations in DNA mismatch repair genes: Implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 2004; 24: 10391047.
  • 21
    Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000; 10: 144150.
  • 22
    Huang X,King MA,Halicka HD,Traganos F,Okafuji M,Darzynkiewicz Z. Histone H2AX phosphorylation induced by selective photolysis of BrdU-labeled DNA with UV light: Relation to cell cycle phase. Cytometry A 2004; 62: 17.
  • 23
    Cappella P,Gasparri F,Pulici M,Moll J. A novel method based on click chemistry, which overcomes limitations of cell cycle analysis by classical determination of BrdU incorporation, allowing multiplex antibody staining. Cytometry A 2008; 73: 626636.
  • 24
    Brockhoff G,Heiss P,Schlegel J,Hofstaedter F,Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001; 44: 338348.
  • 25
    Vermes I,Haanen C,Steffens-Nakken H,Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 3951.
  • 26
    Bjursell G,Reichard P. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J Biol Chem 1973; 248: 39043909.
  • 27
    Cleaver JE. The relationship between the rate of DNA synthesis and its inhibition by ultraviolet light in mammalian cells. Radiat Res 1967; 30: 795810.
  • 28
    Kaufman ER,Davidson RL. Biological and biochemical effects of bromodeoxyuridine and deoxycytidine on Syrian hamster melanoma cells. Somatic Cell Genet 1978; 4: 587601.
  • 29
    Endl E,Steinbach P,Knuchel R,Hofstadter F. Analysis of cell cycle-related Ki-67 and p120 expression by flow cytometric BrdUrd-Hoechst/7AAD and immunolabeling technique. Cytometry 1997; 29: 233241.
  • 30
    Clute P,Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999; 1: 8287.
  • 31
    Soto D,Sukumar S. Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Methods Appl 1992; 2: 9698.
  • 32
    Oh SJ,Jung JY,Shim SS,Im MY,Kim HD,Chung SY,Yoon JH. Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function. Mol Cells 2000; 10: 275280.
  • 33
    Martin AC,Facchiano AM,Cuff AL,Hernandez-Boussard T,Olivier M,Hainaut P,Thornton JM. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002; 19: 149164.
  • 34
    Blandino G,Levine AJ,Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477485.
  • 35
    Tarnok A,Bocsi J,Brockhoff G. Cytomics–importance of multimodal analysis of cell function and proliferation in oncology. Cell Prolif 2006; 39: 495505.